<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Akcea Therapeutics, Inc.

    Akcea Therapeutics, Inc.

    Akcea Therapeutics is a development and commercialization company focused on helpi...

    Akcea Therapeutics is a development and commerc...

    Filing Type:    PU
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    Aerie Pharmaceuticals, Inc.

    Aerie Pharmaceuticals, Inc.

    Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...

    Aerie Pharmaceuticals is an ophthalmic pharmace...

    Filing Type:    PU
    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...

    Cellect Biotechnology Ltd. was founded in 2011 ...

    Filing Type:    PU
    BioCardia, Inc.

    BioCardia, Inc.

    BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...

    BioCardia, Inc., headquartered in San Carlos, C...

    Filing Type:    PU
    Allogene Therapeutics, Inc.

    Allogene Therapeutics, Inc.

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...

    Allogene Therapeutics is a clinical stage biote...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    MEI Pharma, Inc.

    MEI Pharma, Inc.

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...

    Filing Type:    PU
    Sierra Oncology, Inc.

    Sierra Oncology, Inc.

    Sierra Oncology is a clinical stage drug development company advancing targeted th...

    Sierra Oncology is a clinical stage drug develo...

    Filing Type:    PU
    Principia Biopharma Inc.

    Principia Biopharma Inc.

    We are a late-stage biopharmaceutical company dedicated to bringing transformative...

    We are a late-stage biopharmaceutical company d...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.